{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:01:53Z","timestamp":1788915713445,"version":"build-2803163510"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.blre.2026.101397","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:12:10Z","timestamp":1778548330000},"page":"101397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Challenges in the treatment of adolescent and young adult acute lymphoblastic leukemia: A comprehensive review"],"prefix":"10.1016","volume":"77","author":[{"given":"Madelyn","family":"Burkart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Dinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.blre.2026.101397_bb0005","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101397_bb0010","series-title":"Significant Improvement Of Outcome In Adolescents and Young adults ( AYAs ) Aged 15-35 Years With Acute Lymphoblastic Leukemia ( ALL ) With a Pediatric Derived Adult ALL Protocol\u00a0; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Stu","author":"G\u00f6kbuget","year":"2013"},{"key":"10.1016\/j.blre.2026.101397_bb0015","first-page":"526","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18 \u2013 50 years with newly diagnosed acute lymphoblastic leukemia","volume":"2015","author":"Deangelo","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2026.101397_bb0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: A population- based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980\u20132017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2026.101397_bb0025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.blre.2026.101397_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13153886","article-title":"Why do children with acute lymphoblastic leukemia fare better than adults?","volume":"13","author":"Neaga","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.blre.2026.101397_bb0035","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.blre.2026.101397_bb0040","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.29646","article-title":"Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Ravandi","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2026.101397_bb0045","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2026.101397_bb0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.blre.2026.101397_bb0055","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2026.101397_bb0060","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","article-title":"INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia","volume":"6","author":"Martinelli","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2026.101397_bb0070","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101397_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.30313","article-title":"The prognostic value of IKZF1plus in B-cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial","volume":"70","author":"Kicinski","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.blre.2026.101397_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.89","article-title":"Blinatumomab-induced lineage switch of B-ALL with t(4:11) (q21;q23) KMT2A\/AFF1 into an aggressive AML: pre-and post-switch phenotypic, cytogenetic and molecular analysis","volume":"7","author":"Haddox","year":"2017","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.blre.2026.101397_bb0085","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ajh.25394","article-title":"Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin","volume":"94","author":"Jabbour","year":"2019","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2026.101397_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14081873","article-title":"Early T-Cell Precursor ALL and Beyond: Immature and Ambiguous Lineage T-ALL Subsets","volume":"14","author":"Genesc\u00e0","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.blre.2026.101397_bb0095","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.2023020678","article-title":"Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study","volume":"142","author":"Wood","year":"2023","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2026.101397_bb0100","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood.2023023754","article-title":"NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients","volume":"144","author":"Simonin","year":"2024","journal-title":"Blood"},{"issue":"8027","key":"10.1016\/j.blre.2026.101397_bb0105","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","article-title":"The genomic basis of childhood T-lineage acute lymphoblastic leukemia","volume":"632","author":"P\u00f6l\u00f6nen","year":"2024","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.blre.2026.101397_bb0110","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101397_bb0115","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2020002439","article-title":"Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia","volume":"5","author":"Advani","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2026.101397_bb0120","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41375-023-02115-4","article-title":"Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols","volume":"38","author":"Valtis","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101397_bb0125","doi-asserted-by":"crossref","unstructured":"DuVall A, McNeer JL, Cheung M, et al. ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood Adv 2026. doi:https:\/\/doi.org\/10.1182\/bloodadvances.2021006469.","DOI":"10.1182\/bloodadvances.2021006469"},{"issue":"6","key":"10.1016\/j.blre.2026.101397_bb0130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.19.01086","article-title":"Outcome in children with standard-risk b-cell acute lymphoblastic leukemia: Results of children\u2019s oncology group trial aall0331","volume":"38","author":"Maloney","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2026.101397_bb0135","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.20.00494","article-title":"Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children\u2019s Oncology Group AALL0932","volume":"39","author":"Angiolillo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2026.101397_bb0140","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2021-149478","article-title":"A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children\u2019s Oncology Group Protocol AALL1732","volume":"138","author":"McNeer","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.blre.2026.101397_bb0145","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1200\/JCO.2023.41.16_suppl.10016","article-title":"A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children\u2019s Oncology Group AALL1732","volume":"41","author":"O\u2019Brien","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.blre.2026.101397_bb0150","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2026.101397_bb0155","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 2","key":"10.1016\/j.blre.2026.101397_bb0160","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-171751","article-title":"Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III Natio","volume":"140","author":"Litzow","year":"2022","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.blre.2026.101397_bb0165","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967372.19440.62","article-title":"Consolidation With Blinatumomab Improves Overall and Relapse-Free Survival in Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Impact of Age and Mrd Level in Ecog-Acrin E1910","volume":"7","author":"Litzow","year":"2023","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.blre.2026.101397_bb0170","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","volume":"392","author":"Gupta","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101397_bb0175","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"(January):586-595","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101397_bb0180","doi-asserted-by":"crossref","first-page":"101208","DOI":"10.1016\/j.blre.2024.101208","article-title":"Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia","volume":"66","author":"Burkart","year":"2024","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0185","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101397_bb0190","first-page":"2","article-title":"Safety and activity of revumenib in combination with fludarabine \/ cytarabine ( FLA ) in patients with relapsed \/ refractory acute leukemias","author":"Shukla","year":"2024","journal-title":"Eur Hematol Assoc"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101397_bb0195","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood-2025-1001","article-title":"Revumenib for patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study","volume":"146","author":"Aldoss","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2026.101397_bb0200","first-page":"1105","article-title":"Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"110","author":"Aldoss","year":"2025","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.blre.2026.101397_bb0205","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/ajh.70082","article-title":"Venetoclax in Combination With Pediatric-Inspired Chemotherapy in Adults With Newly Diagnosed Acute Lymphoblastic Leukemia: Results of a Phase I Trial","volume":"100","author":"Valtis","year":"2025","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101397_bb0210","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood-2023-188064","article-title":"Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial","volume":"142","author":"Haddad","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0215","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.blre.2026.101397_bb0220","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","volume":"42","author":"Fo\u00e0","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.blre.2026.101397_bb0225","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"therapy for Ph-positive ALL\u00a0: a propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.blre.2026.101397_bb0235","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-020-00757-5","article-title":"Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults","volume":"21","author":"Patel","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"10.1016\/j.blre.2026.101397_bb0240","doi-asserted-by":"crossref","first-page":"28829","DOI":"10.1002\/pbc.28829","article-title":"Daratumumab in T-cell acute lymphoblastic leukaemia: A case report and review of the literature","volume":"68","author":"Ruhayel","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2026.101397_bb0245","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2026.101397_bb0250","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2021.279851","article-title":"Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study","volume":"107","author":"Cerrano","year":"2022","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.blre.2026.101397_bb0255","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.2024024493","article-title":"Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study","volume":"144","author":"Bhatla","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2026.101397_bb0260","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children\u2019s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.blre.2026.101397_bb0265","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1182\/bloodadvances.2023009976","article-title":"Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2026.101397_bb0270","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101397_bb0275","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"},{"issue":"28","key":"10.1016\/j.blre.2026.101397_bb0280","article-title":"Children \u2019 s Oncology Group AALL0434\u00a0: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia abstract","volume":"38","author":"Dunsmore","year":"2023"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101397_bb0285","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood-2023-190141","article-title":"Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children\u2019s Oncology Group (COG) Studies AALL0434 and AALL1231","volume":"142","author":"Colace","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2026.101397_bb0290","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000858","article-title":"Managing toxicities with asparaginase- \u00ad based therapies in adult ALL\u00a0: summary of an ESMO Open \u2013 Cancer Horizons roundtable discussion","volume":"5","author":"Burke","year":"2020","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.blre.2026.101397_bb0295","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/10428194.2019.1680839","article-title":"Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"61","author":"Derman","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101397_bb0300","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.blre.2026.101397_bb0305","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1002\/cam4.4281","article-title":"Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia","volume":"10","author":"Schulte","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0310","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2352-3026(23)00314-9","article-title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","volume":"11","author":"O\u2019Brien","year":"2024","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101397_bb0315","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT \u2013 a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2026.101397_bb0320","first-page":"328","article-title":"Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study","volume":"136","author":"Orvain","year":"2020","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2026.101397_bb0325","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood-2012-06-379040","article-title":"Has MRD monitoring superseded other prognostic factors in adult ALL\u00a0?","volume":"120","author":"Bruggemann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101397_bb0330","first-page":"227","article-title":"Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia . The Polish Adult Leukemia Group ALL 4-2002 MRD Study","volume":"May","author":"Holowiecki","year":"2008"},{"issue":"11","key":"10.1016\/j.blre.2026.101397_bb0335","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-00383-2","article-title":"Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18\u201365 years: NILG ALL 10\/07","volume":"10","author":"Bassan","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.blre.2026.101397_bb0340","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia A Meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.blre.2026.101397_bb0345","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and metaanalysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2026.101397_bb0350","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","article-title":"Clinical use of measurable residual disease in adult ALL\u00a0: recommendations from a panel of US experts","volume":"9","author":"Short","year":"2025","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.blre.2026.101397_bb0355","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2026.101397_bb0360","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41375-021-01213-5","article-title":"Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALG","volume":"35","author":"Wieduwilt","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101397_bb0365","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41409-022-01595-9","article-title":"Allogeneic transplant compared to pediatric-inspired therapy for Philadelphia chromosome-negative adolescent and adult ALL in first complete remission","volume":"57","author":"Haroon","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.blre.2026.101397_bb0370","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing\u2013based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101397_bb0375","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood-2023-179454","article-title":"Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed\/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R\/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib\/II Study","volume":"142","author":"Roddie","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101397_bb0380","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA Approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O\u2019Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101397_bb0385","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.blre.2026.101397_bb0390","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2026.101397_bb0395","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101397_bb0400","article-title":"Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed\/refractory adult B-cell acute lymphoblastic leukemia (r\/r B-ALL): Top line results of the pivotal FELIX study","volume":"41(16_suppl):7000-7000","author":"Roddie","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101397_bb0405","article-title":"ASH 2026 Guidelines for Management of Relapsed\/Refractory Disease in Adolescents and Young Adults with ALL","volume":"11","author":"O\u2019Dwyer","year":"2026","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.blre.2026.101397_bb0410","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2022016937","article-title":"How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL","volume":"141","author":"Myers","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2026.101397_bb0415","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27660","article-title":"Understanding, measuring, and addressing the financial impact of cancer on adolescents and young adults","volume":"66","author":"Salsman","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.blre.2026.101397_bb0420","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2017-11-778555","article-title":"Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies","volume":"132","author":"Husson","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2026.101397_bb0425","doi-asserted-by":"crossref","first-page":"18354","DOI":"10.1002\/cam4.6435","article-title":"Prevalence and risk of psychological distress, anxiety and depression in adolescent and young adult (AYA) cancer survivors: A systematic review and meta-analysis","volume":"12","author":"Osmani","year":"2023","journal-title":"Cancer Med"},{"issue":"23","key":"10.1016\/j.blre.2026.101397_bb0430","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2014.57.7528","article-title":"Psychosocial and neurocognitive outcomes in adult survivors of adolescent and early young adult cancer: A report from the Childhood Cancer Survivor Study","volume":"33","author":"Prasad","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101397_bb0435","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/cncr.29868","article-title":"Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship","volume":"122","author":"Muffly","year":"2016","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.blre.2026.101397_bb0440","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1002\/cncr.33634","article-title":"Substance use, substance use disorders, and treatment in adolescent and young adult cancer survivors\u2014Results from a national survey","volume":"127","author":"Ji","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.blre.2026.101397_bb0445","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/jayao.2020.0180","article-title":"Suicidal Ideation and Depression Among Adolescent and Young Adult Cancer Patients","volume":"10","author":"Giberson","year":"2021","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"7","key":"10.1016\/j.blre.2026.101397_bb0450","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/cncr.34064","article-title":"Psychological distress and associated additional medical expenditures in adolescent and young adult cancer survivors","volume":"128","author":"Abdelhadi","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101397_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103914","article-title":"Financial toxicity among adolescent and young adult cancer survivors: A systematic review of educational attainment, employment, and income","volume":"183","author":"Di Giuseppe","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"17","key":"10.1016\/j.blre.2026.101397_bb0460","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","article-title":"Nonadherence to oral mercaptopurine and risk of relapse in hispanic and non-hispanic white children with acute lymphoblastic leukemia: A report from the Children\u2019s Oncology Group","volume":"30","author":"Bhatia","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.blre.2026.101397_bb0465","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2014-01-552166","article-title":"6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: A Children\u2019s Oncology Group study","volume":"124","author":"Bhatia","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101397_bb0470","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/217047","article-title":"Medication Adherence Measures: An Overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed Res Int"},{"issue":"14","key":"10.1016\/j.blre.2026.101397_bb0475","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2016-07-726893","article-title":"Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: A Children\u2019s Oncology Group study","volume":"129","author":"Landier","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101397_bb0480","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/jpepsy\/jsw039","article-title":"Measuring medication adherence in pediatric cancer: An approach to validation","volume":"42","author":"Rohan","year":"2017","journal-title":"J Pediatr Psychol"},{"issue":"2","key":"10.1016\/j.blre.2026.101397_bb0485","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28767","article-title":"Daily text message assessments of 6-mercaptopurine adherence and its proximal contexts in adolescents and young adults with leukemia: A pilot study","volume":"68","author":"Psihogios","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.blre.2026.101397_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamanetworkopen.2020.14205","article-title":"Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children with Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"3","author":"Bhatia","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0495","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jpepsy\/jst093","article-title":"Electronic monitoring of medication adherence in early maintenance phase treatment for pediatric leukemia and lymphoma: Identifying patterns of nonadherence","volume":"40","author":"Rohan","year":"2015","journal-title":"J Pediatr Psychol"},{"key":"10.1016\/j.blre.2026.101397_bb0500","article-title":"Maintenance therapy for acute lymphoblastic leukemia\u00a0: basic science and clinical translations","volume":"June","author":"Toksvang","year":"2022"},{"issue":"November","key":"10.1016\/j.blre.2026.101397_bb0505","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1182\/blood-2023-189447","article-title":"Oral Chemotherapy Adherence in Pediatric Acute Lymphoblastic Leukemia (ALL): A Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 16-001","volume":"142","author":"Kahn","year":"2023","journal-title":"Blood"},{"issue":"March","key":"10.1016\/j.blre.2026.101397_bb0510","article-title":"Therapeutic drug monitoring in the treatment of childhood acute lymphoblastic leukemia \u2013 A practical guideline","volume":"5","author":"Vieira","year":"2025","journal-title":"EJC Paediatr Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101397_bb0515","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/13674935231208502","article-title":"Facilitators and barriers to adherence to medical recommendations among adolescents with cancer: A systematic review","volume":"29","author":"Salvador","year":"2025","journal-title":"J Child Health Care"},{"key":"10.1016\/j.blre.2026.101397_bb0520","first-page":"(508)","article-title":"Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023","author":"Emmerich","year":"2024","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.blre.2026.101397_bb0525","series-title":"Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges","volume":"13","author":"Tsilingiris","year":"2024"},{"key":"10.1016\/j.blre.2026.101397_bb0530","article-title":"Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers","volume":"1(1):EVIDoa2100001","author":"Wang","year":"2022","journal-title":"NEJM Evid"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2026.101397_bb0535","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1182\/blood-2024-194050","article-title":"Survival Disparities Among Overweight and Obese Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia in a Large Integrated Healthcare System","volume":"144","author":"Newman","year":"2024","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.blre.2026.101397_bb0540","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2014-08-595389","article-title":"Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia","volume":"124","author":"Orgel","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2026.101397_bb0545","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/0008-5472.CAN-12-4402","article-title":"Adipocytes cause leukemia cell resistance to l-asparaginase via release of glutamine","volume":"73","author":"Ehsanipour","year":"2013","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2026.101397_bb0550","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1200\/JOP.2014.000786","article-title":"If you did not document it, it did not happen: Rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients\u2019 medical records","volume":"11","author":"Quinn","year":"2015","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.blre.2026.101397_bb0555","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/01.HS9.0000849692.85775.22","article-title":"P1709: Fertility Preservation for Young Adult Acute Lymphoblastic Leukemias in Italy: a Campus All Survey","volume":"6","author":"Giglio","year":"2022","journal-title":"HemaSphere"},{"issue":"25","key":"10.1016\/j.blre.2026.101397_bb0560","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1200\/JCO.2009.23.0250","article-title":"Physician Referral for Fertility Preservation in Oncology Patients: A National Study of Practice Behaviors","volume":"27","author":"Quinn","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2026.101397_bb0565","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1002\/cncr.29328","article-title":"Fertility preservation knowledge, counseling, and actions among adolescent and young adult patients with cancer: A population-based study","volume":"121","author":"Shnorhavorian","year":"2015","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.blre.2026.101397_bb0570","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility Preservation in People With Cancer: ASCO Guideline Update","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2026.101397_bb0575","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.25229","article-title":"Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens","volume":"93","author":"Siegel","year":"2018","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.blre.2026.101397_bb0580","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1200\/JCO.2006.06.5888","article-title":"American Society of Clinical Oncology recommendations on fertility preservation in cancer patients","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2023.08.032","article-title":"Safety of ovarian cryopreservation and transplantation in patients with acute leukemia: a case series","volume":"230","author":"S\u00f6nmezer","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.blre.2026.101397_bb0590","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.fertnstert.2016.04.031","article-title":"Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria","volume":"106","author":"Meirow","year":"2016","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-021-00936-4","article-title":"Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients","volume":"15","author":"Zver","year":"2022","journal-title":"J Ovarian Res"},{"issue":"3","key":"10.1016\/j.blre.2026.101397_bb0600","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JOP.2017.028134","article-title":"Interventions to address sexual problems in people with cancer: American society of clinical oncology clinical practice guideline adaptation summary","volume":"14","author":"Carter","year":"2018","journal-title":"J Oncol Pract"},{"issue":"4","key":"10.1016\/j.blre.2026.101397_bb0605","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/jayao.2017.0011","article-title":"Supporting Adolescents and Young Adults with Cancer: Oncology Provider Perceptions of Adolescent and Young Adult Unmet Needs","volume":"6","author":"Kirchhoff","year":"2017","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101397_bb0610","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/cam4.666","article-title":"Discussions about reproductive and sexual health among young adult survivors of cancer","volume":"5","author":"Wang","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2026.101397_bb0615","article-title":"A qualitative study of sexual and reproductive health communication with adolescent and young adult oncology patients","volume":"66(6):27673","author":"Frederick","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"21","key":"10.1016\/j.blre.2026.101397_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215243","article-title":"A Negative Body Image among Adolescent and Young Adult (AYA) Cancer Survivors: Results from the Population-Based SURVAYA Study","volume":"14","author":"Saris","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.blre.2026.101397_bb0625","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1002\/cncr.27512","article-title":"Positive and negative psychosocial impact of being diagnosed with cancer as an adolescent or young adult","volume":"118","author":"Bellizzi","year":"2012","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.blre.2026.101397_bb0630","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1182\/bloodadvances.2022007197","article-title":"Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia","volume":"6","author":"Muffly","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.blre.2026.101397_bb0635","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017052","article-title":"Are survival and mortality rates associated with recruitment to clinical trials in teenage and young adult patients with acute lymphoblastic leukaemia? A retrospective observational analysis in England","volume":"7","author":"Hough","year":"2017","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.blre.2026.101397_bb0640","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1055-9965.EPI-18-0430","article-title":"Causes of inferior outcome in adolescents and young adults with acute lymphoblastic leukemia: Across oncology services and regardless of clinical trial enrollment","volume":"27","author":"Wolfson","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.blre.2026.101397_bb0645","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27074","article-title":"Role of clinical trials in survival progress of American adolescents and young adults with cancer-and lack thereof","volume":"65","author":"Bleyer","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0650","first-page":"154","article-title":"Adolescent angst: Enrollment on clinical trials","volume":"2018","author":"Keegan","year":"2018","journal-title":"Hematol (United States)"},{"issue":"30","key":"10.1016\/j.blre.2026.101397_bb0655","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1200\/JCO.2011.36.2954","article-title":"Clinical trial participation and time to treatment among adolescents and young adults with cancer: Does age at diagnosis or insurance make a difference?","volume":"29","author":"Parsons","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2026.101397_bb0660","article-title":"Barriers and Facilitators to Adolescent and Young Adult Cancer Trial Enrollment: NCORP Site Perspectives","volume":"5","author":"Siembida","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0665","first-page":"1","article-title":"Shared barriers and facilitators to enrollment of adolescents and young adults on cancer clinical trials","volume":"12","author":"Mittal","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2026.101397_bb0670","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/jayao.2013.0011","article-title":"A Qualitative Study of Phase III Cancer Clinical Trial Enrollment Decision-Making: Perspectives from Adolescents, Young Adults, Caregivers, and Providers","volume":"3","author":"Barakat","year":"2014","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101397_bb0675","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/jayao.2019.0100","article-title":"Factors Impacting Fertility Preservation in Adolescents and Young Adults with Cancer: A Retrospective Study","volume":"9","author":"Mobley","year":"2020","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"8","key":"10.1016\/j.blre.2026.101397_bb0680","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/bloodadvances.2017014944","article-title":"Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: A population-based study","volume":"2","author":"Muffly","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2026.101397_bb0685","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/OP.23.00328","article-title":"Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL","volume":"20","author":"Wolfson","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"10.1016\/j.blre.2026.101397_bb0690","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/1055-9965.EPI-16-0722","article-title":"Impact of care at NCI comprehensive cancer centers (NCICCC) on outcomes in children, adolescents and young adults (AYA) with hematologic malignancies","volume":"26","author":"Wolfson","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"29","key":"10.1016\/j.blre.2026.101397_bb0695","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1200\/JCO.2006.08.4103","article-title":"Site of oncologic specialty care for older adolescents in Utah","volume":"25","author":"Albritton","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101397_bb0700","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/1055-9965.EPI-21-1388","article-title":"Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis","volume":"31","author":"Berkman","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"10.1016\/j.blre.2026.101397_bb0705","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.3676","article-title":"Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades","volume":"7","author":"Bhatia","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.blre.2026.101397_bb0710","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaa025","article-title":"Late effects in survivors of adolescent and young adult acute lymphoblastic leukemia","volume":"4","author":"Muffly","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"10.1016\/j.blre.2026.101397_bb0715","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/ije\/dyaa184","article-title":"Chronic medical conditions and late effects after acute myeloid leukaemia in adolescents and young adults: a population-based study","volume":"50","author":"Abrah\u00e3o","year":"2021","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.blre.2026.101397_bb0720","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1089\/jayao.2024.0139","article-title":"Transition to Survivorship Care for Adolescents and Young Adults (AYAs) with Acute Leukemia: Provider Perspectives","volume":"14","author":"Flores","year":"2025","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"7","key":"10.1016\/j.blre.2026.101397_bb0725","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.18736","article-title":"Cancer survivorship care in the United States at facilities accredited by the Commission on Cancer","volume":"7","author":"Stal","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:07:28Z","timestamp":1787951248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":145,"alternative-id":["S0268960X26000366"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101397","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in the treatment of adolescent and young adult acute lymphoblastic leukemia: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101397"}}